Jeuveau in Buckhead and Cumming, Georgia

The label says retreatment should be no more frequent than every three months, and the Medication Guide says Jeuveau should not be received more than once every three months. In two one-year open-label safety trials of 922 people, with a median of three treatments each, the side effect profile was similar to the single-dose trials. Your injector will recommend timing based on how you respond.

The label says botulinum toxins may lead to antibodies that reduce the effect of later treatments by inactivating the toxin. Among 1,414 people treated with Jeuveau in its studies, 2 had antibodies before treatment and 2 developed them afterward. The label adds that comparing antibody rates across products may be misleading.

The two label trials enrolled adults aged 18 to 81, including 68 people aged 65 and older. No differences in safety or efficacy were seen between older and younger participants, but the label says there were too few older adults to know whether they respond differently. Ask your injector what to expect.

Each vial contains 100 units of botulinum toxin type A, human serum albumin and sodium chloride, with no preservative. The label says the albumin is a derivative of human blood and carries an extremely remote risk of transmitting viral disease and variant Creutzfeldt-Jakob disease, and that no cases of transmission have been identified for licensed albumin products.

The label lists aminoglycoside antibiotics, other agents that interfere with nerve-to-muscle signals, anticholinergic drugs, other botulinum toxins and muscle relaxants as products that may add to Jeuveau's effects, and says to use them with caution. The Medication Guide asks whether you have had any other botulinum toxin in the last four months. Bring a list of your medicines and your toxin history.

The Jeuveau label lists no activity or positioning rules. For botulinum toxins in general, the American Academy of Dermatology advises not rubbing or massaging the treated areas and waiting two hours before strenuous activity. Follow the written instructions your office gives you, which may be stricter.

One head-to-head trial of 540 adults, funded by Jeuveau's maker, Evolus, compared the two for frown lines. At day 30, 87.2% of Jeuveau patients and 82.8% of Botox patients had none or mild lines, and the authors concluded Jeuveau was noninferior, meaning not meaningfully worse; the trial did not show it was better. The Jeuveau label approves it only for frown lines, and its units are not interchangeable with other brands.